Skip to main content
. Author manuscript; available in PMC: 2016 Jan 15.
Published in final edited form as: Cell. 2014 Dec 31;160(0):324–338. doi: 10.1016/j.cell.2014.12.021

Figure 2. Modeling murine PDA progression with tumor- and metastasis-derived organoids.

Figure 2

(A) H&E staining of murine tissue from which tumor and metastasis organoids were derived (top). Arrowhead indicates metastasis. Scale bars, 50 μm. Digested murine tissues embedded in Matrigel immediately following isolation (middle) and organoids 3 days post-isolation (bottom). Scale bars, 200 μm.

(B) Immunoblots of selected signaling effectors, Kras-GTP and Ras-GTP by RBD-GST pull-down, and Tubulin. PCR confirmation of KrasLSL-G12D recombination in mP, mT, and mM organoids (bottom).

(C) H&E staining of tumors and metastases (met) derived from mT organoid orthotopic transplants. Scale bars, 200 μm (top) and 50 μm (bottom).

(D) Loss of heterozygosity of the wild-type Trp53 allele determined by PCR (top) and immunoblot analysis of Trp53, Smad4, and p16, and Tubulin. mM3L: derived from a liver metastasis.

(E) Karyotypes of organoids and monolayer (2D) cell lines.

See also Figure S2 and Table S2.